{"prompt": "['Official Protocol Title:', 'A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of', 'Pembrolizumab (MK-3475/SCH900475) in Combination with', 'Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line', 'Treatment of Subjects with Extensive Stage Small Cell Lung', 'Cancer(KEYNOTE-604)', 'NCT number:', 'NCT03066778', 'Document Date:', '23-Apr-2019']['Product: MK-3475', '1', 'Protocol/Amendment No.: 604-09', 'THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING', 'TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK', 'SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.,', 'WHITEHOUSE STATION, NJ, U.S.A.', 'SPONSOR:', 'Merk Sharp & Dohme Corp., a subsidiary of Merk & Co., Inc.', '(hereafter referred to as the Sponsor or Merck)', 'One Merk Drive', 'P.O. Box 100', 'Whitehouse Station, New Jersey, 08889-0100, U.S.A.', 'Protocol-specific Sponsor Contact information can be found in the Investigator Trial File', 'Binder (or equivalent).', 'TITLE:', 'A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-', '3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for', 'the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer', '(KEYNOTE-604)', 'IND NUMBER: 116833', 'EudraCT NUMBER: 2016-004309-15', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '2', 'Protocol/Amendment No.: 604-09', 'TABLE OF CONTENTS', 'DOCUMENT HISTORY', '11', 'SUMMARY OF CHANGES', '13', '1.0', 'TRIAL SUMMARY', '15', '2.0', 'TRIAL DESIGN', '16', '2.1', 'Trial Design', '16', '2.2', 'Trial Diagram', '19', '3.0', 'OBJECTIVE(S) & HYPOTHESIS(ES)', '20', '3.1', 'Primary Objective(s) & Hypothesis(es)', '20', '3.2', 'Secondary Objective(s) & Hypothesis(es)', '20', '3.3', 'Exploratory Objectives', '21', '4.0', 'BACKGROUND & RATIONALE', '21', '4.1', 'Background', '21', '4.1.1 Pharmaceutical and Therapeutic Background', '21', '4.1.2', 'Information on Other Trial-related Therapy', '22', '4.1.2.1', 'Etoposide/Platinum Therapy', '22', '4.1.2.2 Prophylactic Cranial Irradiation', '23', '4.2', 'Rationale', '25', '4.2.1', 'Rationale for the Trial and Selected Subject Population', '25', '4.2.2', 'Rationale for Dose Selection/Regimen/Modification', '27', '4.2.2.1 Rationale for the Dose of Pembrolizumab', '27', '4.2.2.2 Rationale for Use of Comparator/Placebo', '28', '4.2.3 Rationale for Efficacy Endpoints', '28', '4.2.3.1', 'Primary Efficacy Endpoints', '28', '4.2.3.2 Secondary Efficacy Endpoints', '29', '4.2.3.3', 'Safety Endpoints', '29', '4.2.3.4', 'Patient Reported Outcomes', '29', '4.2.3.5', 'Immune-related RECIST', '30', '4.2.3.6', 'Planned Exploratory Biomarker Research', '30', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}